Article By:
PropThink
Wednesday, October 29, 2014 9:59 AM EDT
Trillium Therapeutics is an immuno-oncology company developing novel cancer therapeutics. Their primary target, the CD47 antigen, is generating significant attention from industry and academia alike.
In this article: SCTPF, CELG